Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Ford David AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Zago Wagner M.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Walker Karin LOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:54,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Smith Brandon S.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Nguyen TranOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Malecek Michael JOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Kinney Gene G.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:307,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Karp Carol D.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Garren HidekiOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 21, 2024 (filed on Feb 23, 2024)Insider Name:Welch Daniel GOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:132,000Price:--
Filings by filing date
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Ford David AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Zago Wagner M.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Walker Karin LOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:54,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Smith Brandon S.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Nguyen TranOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Malecek Michael JOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Kinney Gene G.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:307,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Karp Carol D.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Garren HidekiOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 21, 2024 (filed on Feb 23, 2024)Insider Name:Welch Daniel GOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:132,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 77 Sir John Rogersons Quay Block C, Grand Canal Docklands DUBLIN D02 T804 |
Tel: | N/A |
Website: | https://www.prothena.com |
IR: | See website |
Key People | ||
Gene G. Kinney President, Chief Executive Officer, Director | Tran B. Nguyen Chief Financial Officer, Chief Strategy Officer | Brandon S. Smith Chief Operating Officer |
Karin L. Walker Chief Accounting Officer | Wagner M. Zago Chief Scientific Officer | Hideki Garren Chief Medical Officer |
Carol D. Karp Chief Regulatory Officer | Michael J. Malecek Chief Legal Officer, Company Secretary |
Business Overview |
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company's pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson's disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer's disease. |
Financial Overview |
For the fiscal year ended 31 December 2023, Prothena Corporation PLC revenues increased 70% to $91.4M. Net loss increased 26% to $147M. Revenues reflect Collaboration revenue increase from $13.9M to $91.3M. Higher net loss reflects Clinical-stage neuroscience segment loss increase of 45% to $191M. Basic Earnings per Share excluding Extraordinary Items decreased from -$2.47 to -$2.76. |
Employees: | 173 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $485.66M as of Dec 31, 2023 |
Annual revenue (TTM): | $91.37M as of Dec 31, 2023 |
EBITDA (TTM): | -$190.11M as of Dec 31, 2023 |
Net annual income (TTM): | -$147.03M as of Dec 31, 2023 |
Free cash flow (TTM): | -$136.72M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 53,720,455 as of Feb 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |